POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDYRheumatology, Mymensingh Medical College, Mymensingh, Bangladesh.
Rheumatology, Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India.
Rheumatology, Mahatma Gandhi Mission Medical College, Navi Mumbai, India.
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Centre for Rheumatic Diseases, King’s College London, London, United Kingdom; Rheumatology Department, King’s College Hospital, London, United Kingdom.
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom; Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paolo, Brazil.
Rheumatology Department, Saint-Joseph University, Beirut, Lebanon; Rheumatology Department, Hotel-Dieu de France Hospital, Beirut, Lebanon.
Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland.
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
Division of Rheumatology, Mayo Clinic, Rochester MN, USA.
Rheumatology, Bristol Medical School Translational Health Sciences, University of Bristol, Bristol, United Kingdom; Department of Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom.
Department of Rheumatology, Division of Medicine, Rayne Institute, University College London, London, United Kingdom; Centre for Adolescent Rheumatology Versus Arthritis, University College London, UCLH, GOSH, London, United Kingdom.
Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom; Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Rheumatology, Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom.
Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia; Rheumatology, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, Manchester, United Kingdom; National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom.
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
Show others and affiliations
2023 (English)In: Rheumatology, ISSN 1462-0324, E-ISSN 1462-0332, Vol. 62, no Suppl. 2, article id kead104.106Article in journal, Meeting abstract (Other academic) Published
Abstract [en]
Background/Aims: Post COVID-19 syndrome (PCS) is an emerging cause of morbidity and poor quality of life in COVID-19 survivors. We aimed to assess the prevalence, risk factors, outcomes, and association with disease flaresof PCS in patients with autoimmune rheumatic diseases (AIRDs) and non-rheumatic autoimmune diseases (nrAIDs), both vulnerable groups understudied in the current literature using data from the 2nd COVID-19 Vaccination in Autoimmune Diseases (COVAD) global multicentre patient self-reported e-survey.
Methods: The survey was circulated from February to July 2022 by the international COVAD Study Group (157 collaborators from 106 countries), and demographics, comorbidities, AIRD/nrAID status, COVID-19 history, vaccination details, and PROMIS physical and mental function were recorded. PCS was defined as symptom resolution time >90 days following acute COVID-19. Predictors of PCS were analysed using regression models for the different groups.
Results: 7666 total respondents completed the survey. Of these, 2650 respondents with complete responses had positive COVID-19 infection, and 1677 (45.0% AIRDs, 12.5% nrAIDs, 42.5% HCs) completed the survey >90 days post acute COVID-19. Of these, 136 (8.1%) had PCS. Prevalence of PCS was higher in AIRDs (10.8%) than healthy controls HCs (5.3%) (OR: 2.1; 95%CI: 1.4-3.1, p ¼ 0.002).
Across the entire cohort, a higher risk of PCS was seen in women (OR: 2.9; 95%CI: 1.1-7.7, p ¼ 0.037), patients with long duration of AIRDs/nrAIDs (OR 1.01; 95%CI: 1.0-1.02, p ¼ 0.016), those with comorbidities (OR: 2.8; 95%CI: 1.4-5.7, p ¼ 0.005), and patients requiring oxygen supplementation for severe acute COVID-19 (OR: 3.8; 95%CI: 1.1-13.6, p ¼ 0.039).
Among patients with AIRDs, comorbidities (OR 2.0; 95%CI: 1.08-3.6, p ¼ 0.026), and advanced treatment (OR: 1.9; 95%CI: 1.08-3.3, p ¼ 0.024), or intensive care (OR: 3.8; 95%CI: 1.01-14.4, p ¼ 0.047) for severe COVID-19 were risk factors for PCS.
Notably, patients who developed PCS had poorer PROMIS global physical [15 (12-17) vs 12 (9-15)] and mental health [14 (11-16) vs 11 (8-14)] scores than those without PCS.
Conclusion: Individuals with AIRDs have a greater risk of PCS than HCs. Associated comorbid conditions, and advanced treatment or intensive care unit admission for severe COVID-19 confer a higher risk of PCS. It is imperative to identify risk factors for PCS for immediate multidisciplinary management in anticipation of poor physical and mental health.
Place, publisher, year, edition, pages
Oxford University Press, 2023. Vol. 62, no Suppl. 2, article id kead104.106
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:oru:diva-109801ISI: 001082840200107OAI: oai:DiVA.org:oru-109801DiVA, id: diva2:1813234
Conference
British Society for Rheumatology Annual Conference (BSR 2023), Manchester, UK, April 24-26, 2023
2023-11-202023-11-202025-02-18Bibliographically approved